Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (111-120 of 284) with videos related to

Pageof 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 21, 2012
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerDavid Jackman, William Pao, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancerGautam Maulik, Takashi Kijima, Patrick C Ma, et al.
Journal for Immunotherapy of Cancer|March 30, 2019
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancerBiagio Ricciuti, Sasha Kravets, Suzanne E Dahlberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan, Anderson J Ryan, Helen Mann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
The New England Journal of Medicine|February 25, 2005
EGFR mutation and resistance of non-small-cell lung cancer to gefitinibSusumu Kobayashi, Titus J Boggon, Tajhal Dayaram, et al.
The Oncologist|February 9, 2007
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testingLecia V Sequist, Victoria A Joshi, Pasi A Jänne, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2014
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumorsCurtis R Chong, Lori J Wirth, Mizuki Nishino, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|August 14, 2012
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screeningPamela M McMahon, Chung Yin Kong, Bruce E Johnson, et al.
Pageof 29

Showing results (111-120 of 284) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|December 21, 2012
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerDavid Jackman, William Pao, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancerGautam Maulik, Takashi Kijima, Patrick C Ma, et al.
Journal for Immunotherapy of Cancer|March 30, 2019
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancerBiagio Ricciuti, Sasha Kravets, Suzanne E Dahlberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan, Anderson J Ryan, Helen Mann, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
The New England Journal of Medicine|February 25, 2005
EGFR mutation and resistance of non-small-cell lung cancer to gefitinibSusumu Kobayashi, Titus J Boggon, Tajhal Dayaram, et al.
The Oncologist|February 9, 2007
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testingLecia V Sequist, Victoria A Joshi, Pasi A Jänne, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2014
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumorsCurtis R Chong, Lori J Wirth, Mizuki Nishino, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|August 14, 2012
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screeningPamela M McMahon, Chung Yin Kong, Bruce E Johnson, et al.
Pageof 29